New Radiochemicals Facility to be Located in Cardiff

In support of the acquisition of Amersham Radiolabeling Services from GE Healthcare, (ILM July 2009), Quotient plans to invest up to £15 million in a new state-of-the-art-laboratory in Cardiff. Completion of this new facility is timed to coincide with GE Healthcare ending its radiolabeling operations at the end of March 2010, thus minimising any impact on customers. Approximately 75 Amersham Radiolabeling Services scientific and commercial staff with over 1,000 combined years of experience in the custom synthesis of radiochemicals will transfer to Quotient. To ensure continuity of service to customers, the transfer of operations and staff will take place in three stages. Currently the global sales operations will transfer to Quotient, with the tritium and carbon-14 radiolabeling services transferring to Quotient by the end of 2009 and March 2010 respectively.

Following completion of the new Cardiff facility, Quotient will have over 600 staff across its UK facilities. With its existing strong client base in Europe, the US and Japan, the principal focus of Quotient Bioresearch will be to provide a unique and comprehensive range of early-stage drug development services to a broad range of customers. Stephen Lewinton, current Managing Director of the Drug Development Services Group at Quotient, has been appointed as the Managing Director of Quotient Chemistry & Metabolism.